GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (NAS:KTRA) » Definitions » Intrinsic Value: Projected FCF

Kintara Therapeutics (Kintara Therapeutics) Intrinsic Value: Projected FCF : $-42.00 (As of May. 15, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Kintara Therapeutics Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-15), Kintara Therapeutics's Intrinsic Value: Projected FCF is $-42.00. The stock price of Kintara Therapeutics is $0.1304. Therefore, Kintara Therapeutics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Kintara Therapeutics's Intrinsic Value: Projected FCF or its related term are showing as below:

KTRA's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.45
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Kintara Therapeutics Intrinsic Value: Projected FCF Historical Data

The historical data trend for Kintara Therapeutics's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Intrinsic Value: Projected FCF Chart

Kintara Therapeutics Annual Data
Trend Dec13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -966.07 -279.11 -179.13 -130.26 -110.55

Kintara Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -110.44 -109.82 -110.55 -107.74 -42.00

Competitive Comparison of Kintara Therapeutics's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Kintara Therapeutics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Price-to-Projected-FCF falls into.



Kintara Therapeutics Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Kintara Therapeutics's Free Cash Flow(6 year avg) = $-12.24.

Kintara Therapeutics's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)/0.8)/Shares Outstanding (Diluted Average)
=(14.862653310476*-12.24272+-0.164/0.8)/4.337
=-42.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kintara Therapeutics  (NAS:KTRA) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Kintara Therapeutics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.1304/-42.002375590784
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kintara Therapeutics Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics (Kintara Therapeutics) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Executives
Robert Hoffman director, officer: President and CEO ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Anthony Scott Praill officer: Chief Financial Officer 2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3
Saiid Zarrabian director, officer: Head of Strategic Partnerships P.O. BOX 675765, RANCHO SANTA FE CA 92067
Laura L. Johnson director C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Toth Robert Joseph Jr director 543 LOMBARD ST, SAN FRANCISCO CA 94133
Dennis M Brown officer: Chief Scientific Officer 100 SAN MATEO DR, MENLO PARK CA 94025
Keith Murphy director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
John Liatos director, officer: SVP, Business Development 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
John K Bell director 38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8
Napoleone Ferrara director 550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101
Lynda Sarah Cranston director 4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3
Erich Mohr director 8300 GREENSBORO DRIVE, MCLEAN VA 22102
Jeffrey Bacha director SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010